MIST vs. HUMA, RZLT, UPXI, TERN, ARCT, CMPX, ATXS, SNDL, GOSS, and MBX
Should you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Humacyte (HUMA), Rezolute (RZLT), Upexi (UPXI), Terns Pharmaceuticals (TERN), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), Astria Therapeutics (ATXS), SNDL (SNDL), Gossamer Bio (GOSS), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry.
Milestone Pharmaceuticals vs. Its Competitors
Milestone Pharmaceuticals (NASDAQ:MIST) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Humacyte's return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.
Milestone Pharmaceuticals presently has a consensus target price of $7.00, suggesting a potential upside of 264.58%. Humacyte has a consensus target price of $11.71, suggesting a potential upside of 407.11%. Given Humacyte's stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Milestone Pharmaceuticals.
In the previous week, Humacyte had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 3 mentions for Humacyte and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.62 beat Humacyte's score of 0.38 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.
Milestone Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500.
Milestone Pharmaceuticals has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Humacyte beats Milestone Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Milestone Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Milestone Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MIST) was last updated on 7/2/2025 by MarketBeat.com Staff
Free MIST Stock Alerts